Testing new blood and tissue markers to assess thyroid nodule cancer risk
Studies blood and surgical samples from adults with unclear thyroid nodules to find cancer markers.
Key facts
- Who runs it
- University of Cagliari
- Where
- Cagliari, ItalySee the site
- Trial code
- Registry title
- Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features
- Status
- Not yet recruiting
- People taking part
- 256 people, planned
- Started
- 1 Jan 2023
- Expected to end
- 31 Dec 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Multiomic analyses of blood and surgical specimens
- Record updated
- 23 June 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with thyroid nodules that doctors cannot clearly call benign or cancer (Bethesda Class III or IV). Blood and surgical samples are studied to find new cancer markers.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Indeterminate thyroid nodules, Bethesda Class III or Class IV
Main reasons for not taking part
- Another thyroid nodule of Bethesda Class V or Class VI
- Lymph node metastases found before surgery in the central or lateral neck
- Distant metastases
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda Classification of thyroid nodules)
Who cannot take part
- Patients with concomitant thyroid nodules of Bethesda Class V or Class VI
- Patients with preoperative diagnosis of lymph node metastases of central or lateral neck compartment
- Patients with distant metastases
Where in Italy
- AOU CagliariCagliari, ItalyNo longer taking part
About the trial
What the trial wants to find out
Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.
The 2 groups in the trial
- Thyroid carcinoma
Patients with indeterminate thyroid nodule and pathological diagnosis of thyroid carcinoma
Treatment: Multiomic analyses of blood and surgical specimens
- Follicular adenoma
Patients with indeterminate thyroid nodule and pathological diagnosis of follicular adenoma
Treatment: Multiomic analyses of blood and surgical specimens
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Novel, Multimodal, Machine-learning Grounded Approach to Assess the Oncological Risk of Indeterminate Thyroid Nodules
- Plain-language title
- Testing new blood and tissue markers to assess thyroid nodule cancer riskGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 23 June 2022